Chemicals & Petrochemicals
Valuation | |
|---|---|
| Market Cap | 3.58 kCr |
| Price/Earnings (Trailing) | 24.98 |
| Price/Sales (Trailing) | 2.54 |
| EV/EBITDA | 13.74 |
| Price/Free Cashflow | 63.69 |
| MarketCap/EBT | 17.85 |
| Enterprise Value | 3.57 kCr |
Fundamentals | |
|---|---|
Growth & Returns | |
|---|---|
| Price Change 1W | -3.7% |
| Price Change 1M | 3.1% |
| Price Change 6M | -28% |
| Price Change 1Y | -36.4% |
| 3Y Cumulative Return | -21.7% |
| 5Y Cumulative Return | -1.8% |
| 7Y Cumulative Return | 15.2% |
| 10Y Cumulative Return | 22.6% |
| Revenue (TTM) |
| 1.41 kCr |
| Rev. Growth (Yr) | 4.9% |
| Earnings (TTM) | 184.3 Cr |
| Earnings Growth (Yr) | -1.2% |
Profitability | |
|---|---|
| Operating Margin | 14% |
| EBT Margin | 14% |
| Return on Equity | 8.96% |
| Return on Assets | 7.9% |
| Free Cashflow Yield | 1.57% |
Cash Flow & Liquidity | |
|---|---|
| Cash Flow from Investing (TTM) | -139.23 Cr |
| Cash Flow from Operations (TTM) | 255.44 Cr |
| Cash Flow from Financing (TTM) | -48.52 Cr |
| Cash & Equivalents | 39.08 Cr |
| Free Cash Flow (TTM) | 69.81 Cr |
| Free Cash Flow/Share (TTM) | 21.55 |
Balance Sheet | |
|---|---|
| Total Assets | 2.33 kCr |
| Total Liabilities | 275.1 Cr |
| Shareholder Equity | 2.06 kCr |
| Current Assets | 848.92 Cr |
| Current Liabilities | 164.2 Cr |
| Net PPE | 1.05 kCr |
| Inventory | 297.5 Cr |
| Goodwill | 0.00 |
Capital Structure & Leverage | |
|---|---|
| Debt Ratio | 0.01 |
| Debt/Equity | 0.02 |
| Interest Coverage | 48.52 |
| Interest/Cashflow Ops | 75.22 |
Dividend & Shareholder Returns | |
|---|---|
| Dividend/Share (TTM) | 11 |
| Dividend Yield | 1% |
| Shares Dilution (1Y) | 0.00% |
| Shares Dilution (3Y) | 0.00% |
Balance Sheet: Strong Balance Sheet.
Profitability: Recent profitability of 13% is a good sign.
Buy Backs: Company has bought back it's stock in the past which is a good thing.
Past Returns: Underperforming stock! In past three years, the stock has provided -21.7% return compared to 12.8% by NIFTY 50.
Growth: Declining Revenues! Trailing 12m revenue has fallen by -5.4% in past one year. In past three years, revenues have changed by -47.2%.
Smart Money: Smart money is losing interest in the stock.
Balance Sheet: Strong Balance Sheet.
Profitability: Recent profitability of 13% is a good sign.
Buy Backs: Company has bought back it's stock in the past which is a good thing.
Past Returns: Underperforming stock! In past three years, the stock has provided -21.7% return compared to 12.8% by NIFTY 50.
Growth: Declining Revenues! Trailing 12m revenue has fallen by -5.4% in past one year. In past three years, revenues have changed by -47.2%.
Smart Money: Smart money is losing interest in the stock.
Investor Care | |
|---|---|
| Dividend Yield | 1% |
| Dividend/Share (TTM) | 11 |
| Shares Dilution (1Y) | 0.00% |
| Earnings/Share (TTM) | 44.25 |
Financial Health | |
|---|---|
| Current Ratio | 5.17 |
| Debt/Equity | 0.02 |
Technical Indicators | |
|---|---|
| RSI (14d) | 36.56 |
| RSI (5d) | 30.7 |
| RSI (21d) | 53.17 |
| MACD Signal | Sell |
| Stochastic Oscillator Signal | Buy |
| SharesGuru Signal | Buy |
| RSI Signal | Hold |
| RSI5 Signal | Hold |
| RSI21 Signal | Hold |
| SMA 5 Signal | Buy |
| SMA 10 Signal |
Summary of Balaji Amines's latest earnings call, featuring management's outlook on business performance, financial results, and analyst Q&A sessions that highlight key strategic initiatives and market challenges.
Balaji Amines Limited's management outlook for the upcoming quarters indicates a gradual improvement in operational performance, primarily driven by the commissioning of new capacities, including the DME plant and N-Methyl Morpholine projects expected in FY2025-26. The company anticipates achieving 8% to 10% volume growth in the second half of FY '26, driven by approvals for DME, DMC, and pharma-grade propylene glycol.
Key forward-looking points provided by management include:
Revenue Figures: For Q2 FY '26, consolidated revenue stood at INR 341 crores, with H1 FY '26 revenue at INR 715 crores.
EBITDA Performance: EBITDA for Q2 FY '26 was INR 67 crores with an improved margin of 19%, while EBITDA for H1 FY '26 stood at INR 131 crores, translating to an 18% margin.
Projected Growth: The company foresees a minimum 15% growth in value and volume as most plants are expected to be operational by the next financial year, thereby enhancing production capabilities.
Expansion Plans: Balaji Specialty Chemicals Limited's INR 750 crores expansion plan includes a brownfield project for EDA-based products, with Unit 1 slated for commissioning by September 2026 and Unit 2 by December 2026.
Market Dynamics: Despite current global uncertainties and moderated demand in specific segments, the long-term outlook is optimistic owing to rising demand in specialty chemicals and import substitution opportunities in India.
Financial Management: The company remains a zero-debt entity with ongoing projects funded through internal accruals, reinforcing its strong balance sheet.
Management emphasized high-value products, disciplined capital allocation, and process innovation as key growth drivers while maintaining stable realizations in the near term.
Understand Balaji Amines ownership landscape with insights into key distribution patterns, offering investors a clear view of stakeholder dynamics.
| Shareholder Name | Holding % |
|---|---|
| ANDE PRATHAP REDDY | 15.34% |
| APR HOLDING AND INVESTMENTS LLP | 14.74% |
| ANDE SRINIVAS REDDY | 11.29% |
| HEMANTH REDDY GADDAM | 2.52% |
| VIJAYA NALLA | 2.13% |
| VINEEL REDDY NALLA | 2.12% |
| KISHAN REDDY NALLA | 2.11% |
Detailed comparison of Balaji Amines against industry peers, highlighting key financial metrics, valuation ratios, and performance indicators to provide competitive context within the sector.
Ticker | Name | Mkt Cap | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
|---|---|---|---|---|---|---|---|---|---|
| AARTIIND | Aarti Industries | 16.45 kCr | 8.05 kCr | +20.90% | -2.60% | 58.38 | 2.04 | - | - |
| VINATIORGA | Vinati Organics | 15.87 kCr |
Comprehensive comparison against sector averages
BALAMINES metrics compared to Chemicals
| Category | BALAMINES | Chemicals |
|---|---|---|
| PE | 25.91 | 44.71 |
| PS | 2.63 | 4.17 |
| Growth | -5.4 % | 6.2 % |
Balaji Amines is a prominent player in the Specialty Chemicals sector, with its stock ticker being BALAMINES. The company has a significant market capitalization of Rs. 4,168.1 Crores.
Based in Solapur, India, Balaji Amines Limited specializes in the manufacture and sale of a wide range of chemical products, including methylamines, ethylamines, and related derivatives used in specialty chemicals and pharmaceutical excipients.
The company's operations are divided into two key segments: Chemicals and Hotel. Its chemical offerings encompass various products such as:
In addition to its chemical manufacturing, Balaji Amines operates Balaji Sarovar Premiere, a hotel located in Solapur, and offers a range of hospitality services including restaurant and hotel management.
The company caters to numerous industries such as:
Its clientele spans across various countries including the United States, United Kingdom, Canada, Germany, and many others, indicating its strong international presence.
Founded in 1988, Balaji Amines reported a trailing 12-month revenue of Rs. 1,492.2 Crores, with a profit of Rs. 190.6 Crores over the last four quarters. Although it has experienced a revenue decline of 24% over the past three years, the company remains profitable and rewards its investors with a dividend yield of 0.64% annually, recently distributing Rs. 11 per share.
This is an informational page just to provide a quick 'first look' at the stock. You must do your own deeper research. Know your risk appetite. Consult a SEBI-registered financial advisor before making any investment decisions.
| Sell |
| SMA 20 Signal | Sell |
| SMA 50 Signal | Buy |
| SMA 100 Signal | Buy |
BALAMINES vs Chemicals (2021 - 2026)
Question: "What is the status of our LPG blending?" Answer: We have submitted the LPG blending to the government, and it's currently moving through approvals. We're also in the process of obtaining PESO approvals for the cylinders and road tankers.
Question: "How much DME is required in the aerosol industry?" Answer: We estimate the demand for DME in the aerosol industry to be around 30,000 to 35,000 tons. Given its environmentally friendly profile, we foresee promising opportunities in this sector.
Question: "What is the capacity utilization on our EV-based products?" Answer: Currently, our DMC is operating at about 20% capacity. We're providing technical and food-grade propylene glycol and have applied for pharma-grade PG. We plan to start production once we receive approval.
Question: "How confident are you of achieving the 10% volume growth for FY '26?" Answer: We're awaiting approvals for DME blending and battery-grade DMC. With these approvals, we expect to achieve at least 8% to 10% volume growth in H2 FY '26.
Question: "What is the update on the antidumping investigation regarding EDA?" Answer: An oral hearing has occurred, but the case has been reassigned due to a retired officer. We anticipate another hearing by month-end and hope for results by next month.
Question: "How are your realizations trending across major product lines?" Answer: There has been volatility in the prices of methanol and ammonia, with methanol settling below INR 30 and ammonia around INR 47-48. We expect to maintain good margins given our cost advantages.
Question: "What is the current utilization level at Unit 4 and new plants in Specialty Chemicals?" Answer: Methylamines is running at 80-85% utilization, while butylamine is at 30-35%, and DMC is at 20-30%. We're awaiting full ramp-up from battery manufacturers.
Question: "What do you see as the company's overall capacity and potential revenue?" Answer: Once all expansions are operational, we expect a minimum of 15% growth in both volumes and revenues in the next financial year.
Question: "What is the current working capital cycle?" Answer: Our working capital cycle is normal at 60-90 days. We're not facing issues with receivables or inventory buildup as demand normalizes.
Question: "Have you seen any growth in acetonitrile demand?" Answer: We anticipate a consumption growth of about 7-8% for acetonitrile in the domestic market, supported by new GLP drugs and our improved cost-effective production processes.
| VINITHA NALLA | 1.91% |
| MANOHAR DEVABHAKTUNI | 1.85% |
| N RAJESHWAR REDDY | 1.84% |
| GADDAM MADHUMATHI | 1.77% |
| NOMULA SARITA | 1.53% |
| VEERA REDDY YANNAM SRINIVAS REDDY YANNAM | 1.5% |
| RAM REDDY DUNDURAPU | 1.47% |
| VIJAYALAXMI YANNAM VEERA REDDY YANNAM SRINIVAS REDDY YANNAM | 1.25% |
| ACHANTA ANNAPURNA | 0.97% |
| DEEPTI RAJESHWAR REDDY NOMULA | 0.94% |
| DUNDURAPU VANDANA | 0.71% |
| A MEENA DEVI | 0.44% |
| NOMULA EESHAN REDDY | 0.36% |
Distribution across major stakeholders
Distribution across major institutional holders
| 2.31 kCr |
| -5.20% |
| -13.60% |
| 35.83 |
| 6.87 |
| - |
| - |
| ALKYLAMINE | Alkyl Amines Chemicals | 7.95 kCr | 1.57 kCr | +0.20% | -13.10% | 44 | 5.07 | - | - |
| SUDARSCHEM | Sudarshan Chemical Indus. | 7.2 kCr | 6.99 kCr | -5.40% | -10.80% | 42.83 | 1.03 | - | - |
| GALAXYSURF | Galaxy Surfactants | 6.48 kCr | 4.82 kCr | -8.10% | -25.00% | 22.64 | 1.35 | - | - |
| -11.8% |
| 46 |
| 52 |
| 49 |
| 54 |
| 41 |
| 57 |
| Total profit before tax | -11.8% | 46 | 52 | 49 | 54 | 41 | 57 |
| Current tax | 4.3% | 9.07 | 8.74 | 12 | 24 | 6.24 | 11 |
| Deferred tax | 7.7% | 6.16 | 5.79 | 0 | -10.6 | 3.51 | 4.06 |
| Total tax | 0% | 15 | 15 | 12 | 14 | 9.75 | 15 |
| Total profit (loss) for period | -16.7% | 31 | 37 | 76 | 40 | 31 | 41 |
| Other comp. income net of taxes | - | 0.08 | 0 | 0 | 0.47 | 0 | 0 |
| Total Comprehensive Income | -16.7% | 31 | 37 | 76 | 41 | 31 | 41 |
| Earnings Per Share, Basic | -12.2% | 9.49 | 10.67 | 11.73 | 12.36 | 10.24 | 12.65 |
| Earnings Per Share, Diluted | -12.2% | 9.49 | 10.67 | 11.73 | 12.36 | 10.24 | 12.65 |
| -27.1% |
| 1.86 |
| 2.18 |
| 2.73 |
| 7.04 |
| 5.33 |
| 12 |
| Depreciation and Amortization | 12.1% | 38 | 34 | 31 | 29 | 23 | 24 |
| Other expenses | 1.9% | 268 | 263 | 311 | 309 | 213 | 178 |
| Total Expenses | -3.6% | 1,087 | 1,127 | 1,431 | 1,507 | 930 | 776 |
| Profit Before exceptional items and Tax | -10% | 209 | 232 | 305 | 423 | 310 | 154 |
| Exceptional items before tax | - | 0 | 0 | 0 | 0 | 0 | 4.28 |
| Total profit before tax | -10% | 209 | 232 | 305 | 423 | 310 | 158 |
| Current tax | -17.6% | 43 | 52 | 72 | 111 | 81 | 40 |
| Deferred tax | 22.2% | 9.91 | 8.29 | 6.28 | 3.96 | -3.09 | 4.24 |
| Total tax | -11.9% | 53 | 60 | 78 | 115 | 78 | 44 |
| Total profit (loss) for period | -8.8% | 156 | 171 | 228 | 308 | 232 | 114 |
| Other comp. income net of taxes | 87.5% | 0.27 | -4.84 | -0.16 | 0 | 0 | 0 |
| Total Comprehensive Income | -6.1% | 156 | 166 | 227 | 308 | 232 | 114 |
| Earnings Per Share, Basic | -9% | 48.21 | 52.87 | 70.18 | 95.04 | 71.52 | 35.11 |
| Earnings Per Share, Diluted | -9% | 48.21 | 52.87 | 70.18 | 95.04 | 71.52 | 35.11 |
| 828 |
| 715 |
| 719 |
| 593 |
| 599 |
| Capital work-in-progress | -9.3% | 137 | 151 | 214 | 141 | 153 | 74 |
| Investment property | -2.6% | 4.71 | 4.81 | 4.91 | 5.01 | 5.12 | 5.22 |
| Non-current investments | 0% | 66 | 66 | 66 | 66 | 66 | 66 |
| Loans, non-current | - | 0 | 0 | 0 | 0 | 0 | 0 |
| Total non-current financial assets | -2.8% | 71 | 73 | 80 | 99 | 71 | 70 |
| Total non-current assets | 3.4% | 1,126 | 1,089 | 1,023 | 972 | 865 | 777 |
| Total assets | 1% | 1,868 | 1,850 | 1,741 | 1,736 | 1,566 | 1,551 |
| Total non-current financial liabilities | 428.6% | 1.37 | 1.07 | 1.07 | 1.06 | 2.55 | 1 |
| Provisions, non-current | 82.8% | 3.76 | 2.51 | 1.77 | 4.26 | 1.59 | 1.81 |
| Total non-current liabilities | 10% | 89 | 81 | 76 | 73 | 66 | 63 |
| Borrowings, current | - | 0 | 0 | 0 | 0 | 0 | 0 |
| Total current financial liabilities | -24.3% | 79 | 104 | 76 | 118 | 55 | 82 |
| Provisions, current | 118.1% | 2.57 | 1.72 | 1.34 | 2.87 | 0.18 | 0.25 |
| Current tax liabilities | 509.5% | 2.28 | 1.21 | 2.27 | 2.77 | 4.96 | 0 |
| Total current liabilities | -23% | 88 | 114 | 85 | 128 | 66 | 88 |
| Total liabilities | -9.3% | 177 | 195 | 161 | 202 | 132 | 151 |
| Equity share capital | 0% | 6.48 | 6.48 | 6.48 | 6.48 | 6.48 | 6.48 |
| Total equity | 2.2% | 1,691 | 1,655 | 1,580 | 1,534 | 1,434 | 1,400 |
| Total equity and liabilities | 1% | 1,868 | 1,850 | 1,741 | 1,736 | 1,566 | 1,551 |
| 30.4% |
| 224 |
| 172 |
| 216 |
| 168 |
| - |
| - |
| Proceeds from sales of PPE | 3.1% | 0.06 | 0.03 | 0.15 | 0.27 | - | - |
| Purchase of property, plant and equipment | -29.1% | 157 | 221 | 76 | 148 | - | - |
| Purchase of intangible assets | -72.8% | 1.25 | 1.92 | 0 | 0 | - | - |
| Interest received | -7.7% | 13 | 14 | 3.96 | 0 | - | - |
| Other inflows (outflows) of cash | -155.8% | -33.58 | 63 | 0 | 30 | - | - |
| Net Cashflows From Investing Activities | -22.5% | -179.24 | -146.18 | -132.37 | -117.85 | - | - |
| Payments of lease liabilities | - | 0.02 | 0 | 0 | 0 | - | - |
| Dividends paid | 12.9% | 36 | 32 | 19 | 13 | - | - |
| Interest paid | -27.1% | 1.86 | 2.18 | 2.73 | 7.04 | - | - |
| Other inflows (outflows) of cash | - | 0 | 0 | 0 | 0.45 | - | - |
| Net Cashflows from Financing Activities | -8.3% | -37.52 | -34.58 | -22.17 | -19.55 | - | - |
| Net change in cash and cash eq. | 170.4% | 7.59 | -8.36 | 61 | 30 | - | - |
Analysis of Balaji Amines's financial performance, highlighting revenue trends, growth patterns, and key metrics through quarterly analysis.
Last Updated: Dec 31, 2025
| Description | Share | Value |
|---|---|---|
| Amines & Speciality chemicals | 96.2% | 324.5 Cr |
| Hotel Division | 2.9% | 9.8 Cr |
| Unallocated | 0.9% | 2.9 Cr |
| Total | 337.3 Cr |